250,000 buy @ 4.30p gone through. |
I managed to get some more on the unexpected pullback yesterday.
The company is currently experiencing strong trading , share price is still 50% less than what it was in 2023.
Shares will rebound strongly in 2025. |
You may well be right, I was merely adding some information that I thought relevant.
Although you would have thought that one would follow the other if that were the case. |
Barry (post 59925) I assumed that the PRM advances enable users to do more with the same machine, so the fact that there has been 'no detectable increase in demand' for Mass Spec machines does not mean that PRM's offerings are not in demand.
But I am just (optimistically) guessing. |
Why would anyone have a fred devoted to talking to him/herself? |
Is there a leak??? |
lol! monte1 the troll has resurfaced again. |
“If a tree falls in a forest and no one is around to hear it, does it make a sound?“ |
Manage to BUY a few more @ sub 4p |
The spectrometry segment captured the largest revenue share in 2023. It is also expected to expand further at the highest CAGR of 14.77% during the forecast period. Spectrometry technology is used for identification and characterization of proteins, detection of post-translational modifications, and analysis of protein-protein interactions in proteomics studies. Advancements in mass spectrometry technology, such as increased resolution, speed, and automation, have significantly enhanced its efficiency, making it a preferred tool for proteomics research. Furthermore, the integration of spectrometry techniques with bioinformatics for data analysis has expanded its applications in drug discovery, biomarker identification, and personalized medicine. These factors are anticipated to drive the segment over the forecast period. |
Morning all,I note the ramping has not had much effect on the ole share price,must try harder gents. |
Market Growth: The global proteomics market is expected to reach USD 44.79 billion by 2025 and grow at a robust CAGR of 11.7%, which is projected to reach USD 134.82 billion by 2035.
Europe:
The UK proteomics market is expected to grow at a CAGR of 8.1%, driven by government-backed academic initiatives such as the UK Biobank project and a focus on personalised medicine. |
🎉Exciting News! 🎉 Massive Innovation with Tandem Mass Tag Labeling!
We are thrilled to share that we’ve stabilized TMT and TMTpro labeling reagents as a liquid and have them available, pre-aliquoted in 96-well plates. 🙌💡
🔸 Don’t hassle with preparation. Their ready-to-use in liquid format.
🔸 Designed for flexibility - use the full plate or use just a partial plate. They are resilient for multiple freeze-thaw cycles.
We can't wait to see how these advancements will empower researchers, streamlining work in discovery and targeted quantitative proteomics. 💪🔬 Learn more about Tandem Mass Tag labeling for mass spectrometry. |
I note that someone must have pushed the 'ramp' button this morning.
Perhaps the same avatar that has voted down 59925? |
Trolls on the other thread are getting a bit desperate to say the least , lol!
The current financial year to 31/12/2025 will be a RECORD year for revenue and profits
the share price has been consolidating at around 4.50p and will take off again.
Shares are a STRONG BUY ahead of full year results. |
According to current research, the fastest growing proteomics technique is single-cell proteomics, which allows for the analysis of protein expression within individual cells, significantly expanding the depth of proteomic analysis and opening new avenues for research in areas like cell biology and disease development.
Requires advanced mass spectrometry techniques and sophisticated data analysis pipelines to overcome the low protein quantity per cell. |
"advantages in multiplexing capacity"
Mass spectrometry (MS)-based proteomics have been increasingly implemented in various disciplines of laboratory medicine to identify and quantify biomolecules in a variety of biological specimens. MS-based proteomics is continuously expanding and widely applied in biomarker discovery for early detection, prognosis and markers for treatment response prediction and monitoring. Furthermore, making these advanced tests more accessible and affordable will have the greatest healthcare benefit.
This review article highlights the new paradigms MS-based clinical proteomics has created in microbiology laboratories, cancer research and diagnosis of metabolic disorders. The technique is preferred over conventional methods in disease detection and therapy monitoring for its combined advantages in multiplexing capacity, remarkable analytical specificity and sensitivity and low turnaround time. |
I dont think that is true at all. The business I work for supplies parts to the manufacturer of the Mass Spec machines and there has been no detectable increase in demand, if anything it has shrunk over the last 12 months. |
Although it has lagged until now, the 'mass spec' proteomics market is expected to be the fastest growing sector. PRM is about to take off. |
They have been multiplying 'Plexes' for as long as anyone can remember, not so with turnover. |
We know Proteome Sciences PLC new isotopic DIA reagents at 6-plex will double the current multiplexing available and they have said that there is at least another 20-plex to add to that, totalling a minimum of 26-plex.
This is impressive and addresses a completely new untapped market for Proteome Sciences PLC |
We can see already, the avatar has no idea, the same as everyone else. |
We will see Barry! |
Utter drivel, 'spoken' from a point of total ignorance. |
Hi, Hutch.
Yes. But not vast - probably not more than $1m, or perhaps £1m.
But it depends on what they are targeting, short term cash, or longer-lasting, larger, returns. In the past they have always gone for the latter. (and mostly missed it!) |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
